Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAmortization of GoodwillAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Health Catalyst (HCAT) Share-based Compensation (2018 - 2025)

Health Catalyst (HCAT) has disclosed Share-based Compensation for 8 consecutive years, with $7.0 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Share-based Compensation fell 26.0% year-over-year to $7.0 million, compared with a TTM value of $33.7 million through Sep 2025, down 20.34%, and an annual FY2024 reading of $40.1 million, down 28.03% over the prior year.
  • Share-based Compensation was $7.0 million for Q3 2025 at Health Catalyst, down from $8.3 million in the prior quarter.
  • Across five years, Share-based Compensation topped out at $18.7 million in Q4 2022 and bottomed at $7.0 million in Q3 2025.
  • Average Share-based Compensation over 5 years is $13.5 million, with a median of $13.9 million recorded in 2023.
  • The sharpest move saw Share-based Compensation surged 95.97% in 2021, then tumbled 38.71% in 2024.
  • Year by year, Share-based Compensation stood at $16.4 million in 2021, then increased by 14.17% to $18.7 million in 2022, then tumbled by 30.6% to $13.0 million in 2023, then fell by 16.9% to $10.8 million in 2024, then crashed by 34.9% to $7.0 million in 2025.
  • Business Quant data shows Share-based Compensation for HCAT at $7.0 million in Q3 2025, $8.3 million in Q2 2025, and $7.5 million in Q1 2025.